Why did THAR's EPS remain stagnant in recent quarters?

The EPS of Tharimmune Inc. (THAR) remained stagnant in recent quarters due to a combination of factors: 1. **Revenue Structure**: THAR's revenue structure is a key indicator of its profitability. The company's focus on clinical-stage biotechnology development and the licensing of its therapeutic candidates to Avior Bio, LLC, suggests that the company is still in the early stages of commercialization. This phase typically involves significant investments in research and development, which can offset profits and lead to negative EPS in the short term. 2. **Market Conditions**: The biotechnology sector is highly competitive and subject to market dynamics that can affect profitability. The industry is characterized by high research and development costs, which can lead to fluctuations in earnings per share if not adequately managed with revenue growth. 3. **Strategic Investments**: THAR's strategic investments in its pipeline of therapeutic candidates, such as the development of bispecific antibodies and antibody drug conjugates, require substantial funding. These investments can lead to increased expenses and potentially impact short-term earnings. 4. **Licensing and Collaboration**: THAR's licensing agreement with Avior Bio, LLC, for the development and commercialization of TH104 and TH103, indicates a strategic move to secure future revenue streams. However, the transition from research to commercialization can take time, and the impact on earnings may not be immediate. In conclusion, the EPS of THAR remaining stagnant in recent quarters can be attributed to a combination of factors including its revenue structure, market conditions, strategic investments, and licensing and collaboration efforts. These factors are common in the biotechnology sector and can lead to fluctuations in earnings until the company achieves commercial success with its therapeutic candidates.